How IDEAYA’s Darovasertib NDA Push and Commercial Buildout At IDEAYA Biosciences (IDYA) Has Changed Its Investment Story

• IDEAYA Biosciences recently outlined a busy 2026 for its oncology pipeline, highlighting positive Phase I/II data for darovasertib in first-line HLA-A2 negative metastatic uveal melanoma and plans for an FDA expedited review and NDA submission aimed at accelerated approval.
• Alongside these clinical and regulatory steps, the company is already investing in commercial infrastructure, including sales leadership hires and supply-chain preparation, signaling a move toward potential commercialization of its lead candidate.
• We’ll now examine how IDEAYA’s push toward an NDA for darovasertib shapes the company’s investment narrative and future opportunities.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is IDEAYA Biosciences' Investment Narrative?

To own IDEAYA today, you have to believe that darovasertib can transition from promising data to an approved commercial product while funding a broader oncology pipeline that is still years from profitability. The latest news, with positive Phase I/II results and the FDA agreeing to an expedited review and NDA under RTOR, makes that first pillar feel more concrete and likely sharpens near term catalysts around regulatory timelines, label scope and launch preparation in 2026. At the same time, the story is becoming more execution-heavy: IDEAYA is scaling commercial infrastructure against a backdrop of widening losses, a rich price-to-sales multiple and no clear path to near-term profits. That combination raises the stakes if trial readouts or the FDA process do not go to plan.

However, one specific operational risk could matter more than many shareholders might expect. IDEAYA Biosciences' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Three fair value views from the Simply Wall St Community span from US$52.63 to a very large upper estimate, underlining just how far apart expectations can be. Set against the upcoming darovasertib NDA decision and IDEAYA’s continuing losses, these contrasting opinions give you a wide range of potential outcomes to weigh for the company’s performance.

Explore 3 other fair value estimates on IDEAYA Biosciences - why the stock might be a potential multi-bagger!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free IDEAYA Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.

Searching For A Fresh Perspective?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Find 48 companies with promising cash flow potential yet trading below their fair value.
• This technology could replace computers: discover 28 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com